The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

The menopausal transition may represent an inflection point for worsening of multiple sclerosis (MS) in women, accordi ...

People with multiple sclerosis (MS) face a significantly higher risk of perinatal mental illness compared to those with other ...

Researchers at the University of Colorado Anschutz Medical Campus have found a promising drug candidate that could help ...

The incidence of mental illness was higher among women with MS during both the prenatal period (incidence ratio [IR] 1.26, 95 ...

MS patients who achieve long-term stable disease on disease-modifying therapy may want to stop their medication for varying ...

As the flames approached a nursing home, these employees navigated smoke, ash and embers to push hospital beds or carry ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...

After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...

A new study reveals that people with multiple sclerosis (MS) experience significantly higher rates of mental illness during ...